相关实验视频
Updated: Jun 27, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
FGF21激动剂:一种新兴的治疗方法,用于与代谢功能障碍相关的脂肪肝炎及其他疾病
Stephen A Harrison1, Tim Rolph2, Madeline Knott3
1Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU UK; Pinnacle Clinical Research, San Antonio, Texas, USA.
纤维细胞生长因子21 (FGF21) 类型在治疗与代谢功能障碍相关的脂肪肝炎 (MASH) 方面表现有前途. 这些化合物可以改善MASH解脱和肝纤维化,解决重大未满足的医疗需求.
科学领域:
- 肝病学和代谢疾病
- 药理学和药物开发领域
背景情况:
- 肥胖,2型糖尿病和脂质失调导致了代谢功能障碍相关的脂肪性肝病 (MASLD) /脂肪性肝炎 (MASH) 的流行病.
- 面临风险的MASH患者面临心血管和肝脏相关死亡的风险增加.
- 目前的MASH治疗选择有限,这突出了严重的未满足的医疗需求.
研究的目的:
- 审查用于MASH治疗的纤维细胞生长因子21 (FGF21) 类型的临床前和临床数据.
- 探索FGF21类似物在解决MASH解决和纤维化改善方面的潜力.
- 在代谢性肝病中研究FGF21类型的额外治疗适用性.
主要方法:
- 在MASH模型中评估FGF21类型的临床前研究的系统审查.
- 对临床试验数据的分析,评估MASH患者FGF21类似物的疗效和安全性.
- 探索FGF21类似物对MASH相关的代谢途径的类效应.
主要成果:
- 在临床前和临床研究中,FGF21类似物对MASH解决和肝纤维化改善有显著影响.
- 这些药物表现出有利于代谢功能障碍的类作用.
- 几种FGF21模拟药物候选药物正在进入第三阶段开发.
结论:
- FGF21类似物代表了MASH的有前途的治疗类,可能提供MASH解决和纤维化改善.
- 它们的多方面的作用使它们成为未来MASH治疗策略的关键候选者.
- 对FGF21类似物的进一步研究可能会在治疗代谢性肝脏疾病方面发现更广泛的应用.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
GPCRs Regulate Adenylyl Cylase Activity
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors